Download FREE Report Sample
Download Free sampleA Companion Cancer Diagnostics is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person.
Companion Cancer Diagnostics are co-developed with drugs to aid in selecting or excluding patient groups for treatment with that particular drug on the basis of their biological characteristics that determine responders and non-responders to the therapy.
Companion Cancer Diagnostics Market contains market size and forecasts of Companion Cancer Diagnostics in Global, including the following market information:
Global Companion Cancer Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Companion Cancer Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Breast Cancer Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Companion Cancer Diagnostics include F. Hoffmann-La Roche, Agilent Technologies, QIAGEN, Abbott Laboratories, Almac Group, Danaher Corporation, bioM?rieuxSA and Myriad Genetics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Companion Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Companion Cancer Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Companion Cancer Diagnostics Market Segment Percentages, by Type, 2021 (%)
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Global Companion Cancer Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Companion Cancer Diagnostics Market Segment Percentages, by Application, 2021 (%)
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others
Global Companion Cancer Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Companion Cancer Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Companion Cancer Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Companion Cancer Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche
Agilent Technologies
QIAGEN
Abbott Laboratories
Almac Group
Danaher Corporation
bioM?rieuxSA
Myriad Genetics
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
